



abbvie

AbbVie Pipeline Update

February 3, 2021

AbbVie R&D Pipeline

Phase 1	Phase 2	Registrational / Phase 3	Submitted
<ul style="list-style-type: none"> ■ ABBV-157 (RORγT) PsO ■ ABBV-022 (IL-22) UC ■ ABBV-151 (GARP+TGFβ1) Solid Tumors ■ ABBV-155 (BCL-xL ADC) Solid Tumors ■ ABBV-181 (PD-1) Solid Tumors ■ ABBV-184 (Survivin-CD3) AML, NSCLC ■ ABBV-368 (OX40) Solid Tumors ■ ABBV-467 (MCL) Heme Tumors ■ ABBV-621 (TRAIL) Solid/Heme Tumors ■ ABBV-744 (BET) AML, MF ■ Mivebresib (BET) MF ■ ABBV-927 (CD40) Solid Tumors ■ ABBV-647 (PTK7 ADC) NSCLC ■ ABBV-011 (SEZ6 ADC) SCLC ■ Venclexta (Bcl-2) ALL ■ CCW702 (CD3-PSMA) Prostate Cancer ■ CLBR001/SWI019 (sCAR-T) Heme Tumors ■ GEN1044 (CD3x5T4) Solid Tumors ■ GEN3009 (CD37) Heme Tumors ■ JAB-3068 / JAB-3312 (SHP2) Solid Tumors ■ HPN-217 (CD3-BCMA) MM ■ TNB-383B (CD3-BCMA) MM ■ TTX-030 (CD39) Solid Tumors ■ ABBV-IMAB-TJC4 (CD47) Heme/Solid Tumors ■ ABBV-CLS-579 (PTPN2) Solid Tumors ■ ABBV-CLS-484 (PTPN2) Solid Tumors ■ ABBV-0805 (α-Synuclein) PD ■ AL003 (CD33) AD ■ ABBV-CLS-7262 (eIF2B) Multiple Neuro ■ AGN-231868 (Chemokine) Dry Eye ■ AGN-242428 (Roγ) Dry Eye ■ AGN-241622 (Alpha2) Presbyopia ■ ABBV-4083 (TylAMac) Filarial Diseases ■ CF Triple Combo (CFTR-C1/CFTR-C2/CFTR-P) ■ ABBV-1882 HIV 	<ul style="list-style-type: none"> ■ ABBV-154 (TNF-Steroid ADC) RA ■ Rinvoq (JAK 1) HS ■ Skyrizi (IL-23) HS ■ ABBV-599 (BTK/JAK) SLE ■ Ravagalimab (CD40) UC ■ ALPN-101 (ICOS/CD28) SLE ■ Teliso-V (cMet ADC) NSCLC ■ ABBV-CX-2029 (CD71) Solid/Heme Tumors ■ ABBV-8E12 (Tau) AD ■ Elezanumab (RGMa) MS ■ Elezanumab (RGMa) Stroke ■ Elezanumab (RGMa) SCI ■ AL002 (TREM2) AD ■ BoNTE (SNARE) Glabellar Lines ■ Botox (SNARE) Platysma Prominence ■ Abicipar (VEGF-A) DME ■ Armour Thyroid (T3T4) Hypothyroidism ■ AGN-151607 (SNARE) Afib 	<ul style="list-style-type: none"> ■ Rinvoq (JAK 1) CD ■ Rinvoq (JAK 1) UC ■ Rinvoq (JAK 1) GCA ■ Rinvoq (JAK 1) nr-Axial SpA ■ Skyrizi (IL-23) CD ■ Skyrizi (IL-23) UC ■ Skyrizi (IL-23) PsA ■ Imbruvica (BTK) 1L FL ■ Imbruvica (BTK) 1L MCL ■ Imbruvica (BTK) R/R MCL ■ Imbruvica (BTK) R/R FL/MZL ■ Imbruvica (BTK) 1L CLL ■ Venclexta (BCL-2) 1L CLL ■ Venclexta (BCL-2) AML Maintenance ■ Venclexta (BCL-2) R/R MM t(11;14) ■ Venclexta (BCL-2): MDS ■ Navitoclax (BCL-2/BCL-xL) Myelofibrosis ■ Epcoritamab (CD3xCD20): R/R DLBCL ■ Veliparib (PARP) BRCA Breast Cancer ■ Veliparib (PARP) 1L Ovarian Cancer ■ ABBV-951 (dopamine receptor) PD ■ Atogepant (CGRP) Migraine Prophylaxis ■ Vraylar (D2,5-HT1A, 5-HT2A) aMDD ■ Botox (SNARE) Masseter Prominence ■ NivobotulinumtoxinA (SNARE) Facial Lines ■ HARmonyCa (HA-CaHA) Dermal Filler* ■ AGN-190584 (Muscarinic) Presbyopia ■ Elagolix + Hormonal Add-Back (GnRH) EM ■ Aztreonam/Avibactam (PBP3) Infection 	<ul style="list-style-type: none"> ■ Rinvoq (JAK 1) PsA ■ Rinvoq (JAK 1) AD ■ Rinvoq (JAK 1) AS

*Pivotal study planning in progress for HARmonyCA in U.S.

■	Immunology
■	Oncology
■	Neuroscience
■	Aesthetics
■	Eye Care
■	Targeted Investment

Anticipated Key Pipeline Events

	2021		2022		
Regulatory Approvals	Rinvoq – Atopic Dermatitis Rinvoq – Psoriatic Arthritis Rinvoq – Ankylosing Spondylitis Atogepant – Episodic migraine prevention AGN-190584 – Presbyopia		Skyrizi – CD Skyrizi – PsA Rinvoq – UC ABBV-951 – Advanced PD Vraylar – aMDD		Imbruvica + Venclexta – 1L CLL Imbruvica + Venclexta – R/R MCL Imbruvica – 1L MCL Venclexta – High Risk MDS (AA) Navitoclax – R/R Myelofibrosis (AA)
Regulatory Submissions	Rinvoq UC Skyrizi CD Skyrizi PsA Imbruvica 1L MCL Imbruvica + Venclexta Ph3 1L CLL ABBV-951 PD AGN-190584 Presbyopia Elagolix + Hormonal Add-Back EM		Rinvoq nr-Axial SpA Rinvoq CD Imbruvica + Venclexta R/R MCL Imbruvica r/r FL/MZL (SELENE) Navitoclax R/R MF (Ph2 AA) Navitoclax 1L and R/R MF Venclexta High Risk MDS (AA Ph1/2 data) Venclexta 3L+ MM w/ t(11;14) Vraylar Ph3 aMDD Atogepant – Chronic migraine prevention		
Ph3/Registrational Data Readouts	Skyrizi Ph3 CD induction/maintenance Rinvoq Ph3 UC induction/maintenance Rinvoq Ph3 CD induction Imbruvica Ph3 1L MCL (SHINE) Imbruvica + Venclexta Ph3 1L CLL (GLOW) Venclexta + Imbruvica Ph3 1L CLL (CLL13) Imbruvica + Venclexta Ph3 r/r MCL (SYMPATICO)	Venclexta Ph1/2 High Risk MDS Navitoclax Ph2 ABBV-951 Ph3 PD Vraylar Ph3 aMDD NivobotulinumtoxinA Ph3 Facial Lines	Rinvoq Ph3 CD maintenance Rinvoq Ph3 Axial SpA Venclexta Ph3 3L+ MM t(11;14) (CANOVA) Imbruvica Ph3 r/r FL/MZL (SELENE) Navitoclax Ph3 MF (1L & R/R) Atogepant Ph3 Chronic Migraine Prevention		
Early-Stage POC Data Readouts	Ravagalimab (CD40) UC Ph2 ABBV-157 (ROR γ t) PsO Ph1 Teliso-V (cMet ADC) Solid Tumor Ph2 TNB-383B (CD3-BCMA) Ph1 ABBV-647 (PTK7 ADC) Ph1 ABBV-011 (SEZ6 ADC) Ph1 ABBV-368 (OX40) + TLR9 Ph1 ABBV-151 (GARP/TGF b1) Ph1	TTX-030 (CD39) Ph1 ABBV-155 (Bcl-xLi ADC) Ph1 Eftoza (Trail) Ph1 ABBV-CX-2029 (CD71) ABBV-8E12 (Tau) AD Ph2 Elezanumab (RGMa) MS Ph2 AL003 (CD33) Ph1 Cystic Fibrosis Dual Combo (C1/P) Ph2	ABBV-599 (JAK/BTK) SLE Ph 2 ABBV-184 (SurvivinTCR/CD3) Ph1 ABBV-467 (MCL1) Ph1 ABBV-GMAB-1044 (CD3x5T4) Ph1 ABBV-GMAB-3009 (CD37) Ph1 ABBV-744 (BET) Ph1 CCW702 (CD3-PSMA) Ph1 ABBV-189 (Survivin-CD3) Ph1	HPN-217 (BCMA-CD3) Ph1 CLBR001/SWI019 (CD19 sCAR-T) Ph1 ABBV-CLS-579/484 (PTPN2) Ph1 Elezanumab (RGMa) SCI Ph2 Elezanumab (RGMa) Stroke Ph2 Cystic Fibrosis Triple Combo (C1/C2/P) Ph2 ABBV-1882 HIV Ph1 AGN-151607 (SNARE) Ph2 Afib	